Integrated genomics and metabolomics in lung cancer revealed BCKDK as an upstream regulator of MYC-dependent HK2 transcription, supporting dual BCKDK/HK2 inhibition to counter trametinib resistance (Wu et al., 2025). This evidence concerns the gene HK2 and lung carcinoma.